Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum
To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL...
Gespeichert in:
| Veröffentlicht in: | Journal of Clinical and Experimental Hematopathology 2011, Vol.51(1), pp.29-35 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 29 |
| container_title | Journal of Clinical and Experimental Hematopathology |
| container_volume | 51 |
| creator | Akagi, Tomoaki Takahashi, Naoto Yamaguchi, Kouhei Ishizawa, Kenichi Murai, Kazunori Tajima, Katsushi Ikeda, Kazuhiko Kameoka, Yoshihiro Kameoka, Junnichi Ito, Shigeki Kato, Yuichi Noji, Hideyoshi Shichishima, Tsutomu Itoh, Jugoh Ichinohasama, Ryo Harigae, Hideo Ishida, Yoji Sawada, Kenichi |
| description | To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL, n=48). All patients received CHOP-based chemotherapy without rituximab. PTCL patients presented at a more advanced clinical stage (91% vs. 65%, P |
| doi_str_mv | 10.3960/jslrt.51.29 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3960_jslrt_51_29</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21628858</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-51231c668a0e89500356a80a30e1e81a1f85d4d455ef358e3567ea896771267b3</originalsourceid><addsrcrecordid>eNpVkc2O0zAUhSMEYn5gxR7dPUrHTmLX2QGBmYIqWomwjm6TmyYljiPb0Sgvy7OQTKGIje3r851jSycI3nC2ilPJ7k6us34l-CpKnwXXXCkWpqmIns_nOJFhEil2Fdw4d2IskULGL4OriMtIKaGug1-Z0QPa1pkeTA1b0x_DnKyGrGv7tsQOdqMvjSa3yNlmt4esIW18QxaHCQ7kH4l6-IoD9uQI9uhb6r2Dx9Y38M1Uc8SebDsshg7yMKOug-2kh8ZodIB9BXljZueT4VNb1-M8bNEeCT7-T0Pbw_wwfPdjNcGDNeOw_Gq5yk1jfo6wIY3edOY4wb2xo34VvKixc_T6z34b_Lj_nGebcLt7-JJ92IZlkjAfCh7FvJRSISOVCsZiIVExjBlxUhx5rUSVVIkQVMdC0SyvCVUq12seyfUhvg3enXNLa5yzVBeDbTXaqeCsWFoqnloqBC-idKbfnulhPGiqLuzfWmbg_Rk4OY9HugBofVt29C-Mn5covUhlg7agPv4NAy2o8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><creator>Akagi, Tomoaki ; Takahashi, Naoto ; Yamaguchi, Kouhei ; Ishizawa, Kenichi ; Murai, Kazunori ; Tajima, Katsushi ; Ikeda, Kazuhiko ; Kameoka, Yoshihiro ; Kameoka, Junnichi ; Ito, Shigeki ; Kato, Yuichi ; Noji, Hideyoshi ; Shichishima, Tsutomu ; Itoh, Jugoh ; Ichinohasama, Ryo ; Harigae, Hideo ; Ishida, Yoji ; Sawada, Kenichi</creator><creatorcontrib>Akagi, Tomoaki ; Takahashi, Naoto ; Yamaguchi, Kouhei ; Ishizawa, Kenichi ; Murai, Kazunori ; Tajima, Katsushi ; Ikeda, Kazuhiko ; Kameoka, Yoshihiro ; Kameoka, Junnichi ; Ito, Shigeki ; Kato, Yuichi ; Noji, Hideyoshi ; Shichishima, Tsutomu ; Itoh, Jugoh ; Ichinohasama, Ryo ; Harigae, Hideo ; Ishida, Yoji ; Sawada, Kenichi</creatorcontrib><description>To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL, n=48). All patients received CHOP-based chemotherapy without rituximab. PTCL patients presented at a more advanced clinical stage (91% vs. 65%, P<0.002) with a poorer performance status (26% vs. 17%, P<0.002) than DLBCL patients. The complete response rate among PTCL patients was significantly lower than among DLBCL patients (39% vs. 67%, P<0.008), as was the 3-year overall survival rate (26% vs. 50%, P=0.005), and Cox multivariate analysis revealed immunophenotype, performance status, and extranodal site involved to be significantly associated with shorter overall survival (P=0.045, P=0.007, and P=0.034, respectively). Our findings suggest that PTCL patients tend to have a poor prognosis associated with several initial risk factors. Moreover, the T-cell phenotype itself appears to have a significant impact on overall survival. Thus, standard CHOP chemotherapy may be inadequate for PTCLs, especially in patients with high-risk factors. The development of newly stratified therapies for the treatment of PTCLs would be highly desirable. [J Clin Exp Hematopathol 51(1) : 29-35, 2011]</description><identifier>ISSN: 1346-4280</identifier><identifier>EISSN: 1880-9952</identifier><identifier>DOI: 10.3960/jslrt.51.29</identifier><identifier>PMID: 21628858</identifier><language>eng</language><publisher>Japan: The Japanese Society for Lymphoreticular Tissue Research</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asian Continental Ancestry Group ; CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) ; Cyclophosphamide - therapeutic use ; diffuse large B-cell lymphoma ; Doxorubicin - therapeutic use ; Female ; Humans ; Immunophenotyping ; Kaplan-Meier Estimate ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, T-Cell, Peripheral - drug therapy ; Lymphoma, T-Cell, Peripheral - mortality ; Male ; Middle Aged ; peripheral T-cell lymphomas ; Prednisone - therapeutic use ; Prognosis ; Retrospective Studies ; survival ; Treatment Outcome ; Vincristine - therapeutic use ; Young Adult</subject><ispartof>Journal of Clinical and Experimental Hematopathology, 2011, Vol.51(1), pp.29-35</ispartof><rights>2011 by The Japanese Society for Lymphoreticular Tissue Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-51231c668a0e89500356a80a30e1e81a1f85d4d455ef358e3567ea896771267b3</citedby><cites>FETCH-LOGICAL-c440t-51231c668a0e89500356a80a30e1e81a1f85d4d455ef358e3567ea896771267b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,1879,4012,27910,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21628858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akagi, Tomoaki</creatorcontrib><creatorcontrib>Takahashi, Naoto</creatorcontrib><creatorcontrib>Yamaguchi, Kouhei</creatorcontrib><creatorcontrib>Ishizawa, Kenichi</creatorcontrib><creatorcontrib>Murai, Kazunori</creatorcontrib><creatorcontrib>Tajima, Katsushi</creatorcontrib><creatorcontrib>Ikeda, Kazuhiko</creatorcontrib><creatorcontrib>Kameoka, Yoshihiro</creatorcontrib><creatorcontrib>Kameoka, Junnichi</creatorcontrib><creatorcontrib>Ito, Shigeki</creatorcontrib><creatorcontrib>Kato, Yuichi</creatorcontrib><creatorcontrib>Noji, Hideyoshi</creatorcontrib><creatorcontrib>Shichishima, Tsutomu</creatorcontrib><creatorcontrib>Itoh, Jugoh</creatorcontrib><creatorcontrib>Ichinohasama, Ryo</creatorcontrib><creatorcontrib>Harigae, Hideo</creatorcontrib><creatorcontrib>Ishida, Yoji</creatorcontrib><creatorcontrib>Sawada, Kenichi</creatorcontrib><title>Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum</title><title>Journal of Clinical and Experimental Hematopathology</title><addtitle>J Clin Exp Hematopathol</addtitle><description>To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL, n=48). All patients received CHOP-based chemotherapy without rituximab. PTCL patients presented at a more advanced clinical stage (91% vs. 65%, P<0.002) with a poorer performance status (26% vs. 17%, P<0.002) than DLBCL patients. The complete response rate among PTCL patients was significantly lower than among DLBCL patients (39% vs. 67%, P<0.008), as was the 3-year overall survival rate (26% vs. 50%, P=0.005), and Cox multivariate analysis revealed immunophenotype, performance status, and extranodal site involved to be significantly associated with shorter overall survival (P=0.045, P=0.007, and P=0.034, respectively). Our findings suggest that PTCL patients tend to have a poor prognosis associated with several initial risk factors. Moreover, the T-cell phenotype itself appears to have a significant impact on overall survival. Thus, standard CHOP chemotherapy may be inadequate for PTCLs, especially in patients with high-risk factors. The development of newly stratified therapies for the treatment of PTCLs would be highly desirable. [J Clin Exp Hematopathol 51(1) : 29-35, 2011]</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asian Continental Ancestry Group</subject><subject>CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>diffuse large B-cell lymphoma</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, T-Cell, Peripheral - drug therapy</subject><subject>Lymphoma, T-Cell, Peripheral - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>peripheral T-cell lymphomas</subject><subject>Prednisone - therapeutic use</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>survival</subject><subject>Treatment Outcome</subject><subject>Vincristine - therapeutic use</subject><subject>Young Adult</subject><issn>1346-4280</issn><issn>1880-9952</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc2O0zAUhSMEYn5gxR7dPUrHTmLX2QGBmYIqWomwjm6TmyYljiPb0Sgvy7OQTKGIje3r851jSycI3nC2ilPJ7k6us34l-CpKnwXXXCkWpqmIns_nOJFhEil2Fdw4d2IskULGL4OriMtIKaGug1-Z0QPa1pkeTA1b0x_DnKyGrGv7tsQOdqMvjSa3yNlmt4esIW18QxaHCQ7kH4l6-IoD9uQI9uhb6r2Dx9Y38M1Uc8SebDsshg7yMKOug-2kh8ZodIB9BXljZueT4VNb1-M8bNEeCT7-T0Pbw_wwfPdjNcGDNeOw_Gq5yk1jfo6wIY3edOY4wb2xo34VvKixc_T6z34b_Lj_nGebcLt7-JJ92IZlkjAfCh7FvJRSISOVCsZiIVExjBlxUhx5rUSVVIkQVMdC0SyvCVUq12seyfUhvg3enXNLa5yzVBeDbTXaqeCsWFoqnloqBC-idKbfnulhPGiqLuzfWmbg_Rk4OY9HugBofVt29C-Mn5covUhlg7agPv4NAy2o8w</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Akagi, Tomoaki</creator><creator>Takahashi, Naoto</creator><creator>Yamaguchi, Kouhei</creator><creator>Ishizawa, Kenichi</creator><creator>Murai, Kazunori</creator><creator>Tajima, Katsushi</creator><creator>Ikeda, Kazuhiko</creator><creator>Kameoka, Yoshihiro</creator><creator>Kameoka, Junnichi</creator><creator>Ito, Shigeki</creator><creator>Kato, Yuichi</creator><creator>Noji, Hideyoshi</creator><creator>Shichishima, Tsutomu</creator><creator>Itoh, Jugoh</creator><creator>Ichinohasama, Ryo</creator><creator>Harigae, Hideo</creator><creator>Ishida, Yoji</creator><creator>Sawada, Kenichi</creator><general>The Japanese Society for Lymphoreticular Tissue Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2011</creationdate><title>Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum</title><author>Akagi, Tomoaki ; Takahashi, Naoto ; Yamaguchi, Kouhei ; Ishizawa, Kenichi ; Murai, Kazunori ; Tajima, Katsushi ; Ikeda, Kazuhiko ; Kameoka, Yoshihiro ; Kameoka, Junnichi ; Ito, Shigeki ; Kato, Yuichi ; Noji, Hideyoshi ; Shichishima, Tsutomu ; Itoh, Jugoh ; Ichinohasama, Ryo ; Harigae, Hideo ; Ishida, Yoji ; Sawada, Kenichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-51231c668a0e89500356a80a30e1e81a1f85d4d455ef358e3567ea896771267b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asian Continental Ancestry Group</topic><topic>CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>diffuse large B-cell lymphoma</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, T-Cell, Peripheral - drug therapy</topic><topic>Lymphoma, T-Cell, Peripheral - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>peripheral T-cell lymphomas</topic><topic>Prednisone - therapeutic use</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>survival</topic><topic>Treatment Outcome</topic><topic>Vincristine - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akagi, Tomoaki</creatorcontrib><creatorcontrib>Takahashi, Naoto</creatorcontrib><creatorcontrib>Yamaguchi, Kouhei</creatorcontrib><creatorcontrib>Ishizawa, Kenichi</creatorcontrib><creatorcontrib>Murai, Kazunori</creatorcontrib><creatorcontrib>Tajima, Katsushi</creatorcontrib><creatorcontrib>Ikeda, Kazuhiko</creatorcontrib><creatorcontrib>Kameoka, Yoshihiro</creatorcontrib><creatorcontrib>Kameoka, Junnichi</creatorcontrib><creatorcontrib>Ito, Shigeki</creatorcontrib><creatorcontrib>Kato, Yuichi</creatorcontrib><creatorcontrib>Noji, Hideyoshi</creatorcontrib><creatorcontrib>Shichishima, Tsutomu</creatorcontrib><creatorcontrib>Itoh, Jugoh</creatorcontrib><creatorcontrib>Ichinohasama, Ryo</creatorcontrib><creatorcontrib>Harigae, Hideo</creatorcontrib><creatorcontrib>Ishida, Yoji</creatorcontrib><creatorcontrib>Sawada, Kenichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Clinical and Experimental Hematopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akagi, Tomoaki</au><au>Takahashi, Naoto</au><au>Yamaguchi, Kouhei</au><au>Ishizawa, Kenichi</au><au>Murai, Kazunori</au><au>Tajima, Katsushi</au><au>Ikeda, Kazuhiko</au><au>Kameoka, Yoshihiro</au><au>Kameoka, Junnichi</au><au>Ito, Shigeki</au><au>Kato, Yuichi</au><au>Noji, Hideyoshi</au><au>Shichishima, Tsutomu</au><au>Itoh, Jugoh</au><au>Ichinohasama, Ryo</au><au>Harigae, Hideo</au><au>Ishida, Yoji</au><au>Sawada, Kenichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum</atitle><jtitle>Journal of Clinical and Experimental Hematopathology</jtitle><addtitle>J Clin Exp Hematopathol</addtitle><date>2011</date><risdate>2011</risdate><volume>51</volume><issue>1</issue><spage>29</spage><epage>35</epage><pages>29-35</pages><issn>1346-4280</issn><eissn>1880-9952</eissn><abstract>To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL, n=48). All patients received CHOP-based chemotherapy without rituximab. PTCL patients presented at a more advanced clinical stage (91% vs. 65%, P<0.002) with a poorer performance status (26% vs. 17%, P<0.002) than DLBCL patients. The complete response rate among PTCL patients was significantly lower than among DLBCL patients (39% vs. 67%, P<0.008), as was the 3-year overall survival rate (26% vs. 50%, P=0.005), and Cox multivariate analysis revealed immunophenotype, performance status, and extranodal site involved to be significantly associated with shorter overall survival (P=0.045, P=0.007, and P=0.034, respectively). Our findings suggest that PTCL patients tend to have a poor prognosis associated with several initial risk factors. Moreover, the T-cell phenotype itself appears to have a significant impact on overall survival. Thus, standard CHOP chemotherapy may be inadequate for PTCLs, especially in patients with high-risk factors. The development of newly stratified therapies for the treatment of PTCLs would be highly desirable. [J Clin Exp Hematopathol 51(1) : 29-35, 2011]</abstract><cop>Japan</cop><pub>The Japanese Society for Lymphoreticular Tissue Research</pub><pmid>21628858</pmid><doi>10.3960/jslrt.51.29</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-4280 |
| ispartof | Journal of Clinical and Experimental Hematopathology, 2011, Vol.51(1), pp.29-35 |
| issn | 1346-4280 1880-9952 |
| language | eng |
| recordid | cdi_crossref_primary_10_3960_jslrt_51_29 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) Cyclophosphamide - therapeutic use diffuse large B-cell lymphoma Doxorubicin - therapeutic use Female Humans Immunophenotyping Kaplan-Meier Estimate Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, T-Cell, Peripheral - drug therapy Lymphoma, T-Cell, Peripheral - mortality Male Middle Aged peripheral T-cell lymphomas Prednisone - therapeutic use Prognosis Retrospective Studies survival Treatment Outcome Vincristine - therapeutic use Young Adult |
| title | Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A52%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Long-Term%20Clinical%20Outcomes%20of%20CHOP%20Chemotherapy%20between%20Japanese%20Patients%20with%20Nodal%20Peripheral%20T-Cell%20Lymphomas%20and%20Those%20with%20Diffuse%20Large%20B-Cell%20Lymphoma%20in%20the%20Study%20Group%20of%20the%20Tohoku%20Hematology%20Forum&rft.jtitle=Journal%20of%20Clinical%20and%20Experimental%20Hematopathology&rft.au=Akagi,%20Tomoaki&rft.date=2011&rft.volume=51&rft.issue=1&rft.spage=29&rft.epage=35&rft.pages=29-35&rft.issn=1346-4280&rft.eissn=1880-9952&rft_id=info:doi/10.3960/jslrt.51.29&rft_dat=%3Cpubmed_cross%3E21628858%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21628858&rfr_iscdi=true |